Dejan Vidovic Gordon A Simms Sylvia Pasternak Mark Walsh Kevork Peltekian John Stein Lucy K Helyer Carman A Giacomantonio
10.3389/fimmu.2021.678028
Front Immunol
2021 May 27;12:678028.
aldara cutaneous squamous cell carcinoma (cscc) imiquimod interleukin-2 (il2) intralesional intralesional il-2 intralesional immunotherapy organ transplant recipient
CC BY
https://pubmed.ncbi.nlm.nih.gov/34122442/
Antineoplastic Agents / adverse effects Carcinoma, Squamous Cell / drug therapy Imiquimod / adverse effects Immunocompromised Host Interleukin-2 / adverse effects Kidney Transplantation Liver Transplantation Skin Neoplasms / drug therapy Transplant Recipients
Antineoplastic Agents / adverse effects Carcinoma, Squamous Cell / drug therapy Imiquimod / adverse effects Immunocompromised Host Interleukin-2 / adverse effects Kidney Transplantation Liver Transplantation Skin Neoplasms / drug therapy Transplant Recipients Case Reports Review Administration, Cutaneous Aged Antineoplastic Agents / administration & dosage Carcinoma, Squamous Cell / immunology Graft Rejection / prevention & control Humans Imiquimod / administration & dosage Immunosuppression Therapy / adverse effects Infusions, Intralesional Interleukin-2 / administration & dosage Male Neoplasm Recurrence, Local / drug therapy Skin Neoplasms / immunology Treatment Outcome Antineoplastic Agents Interleukin-2 Imiquimod
PMC8190543
34122442
Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient
2021